Understanding Recommendations for HER2+ Breast Cancer Treatment in Canada HER2-positive (HER2+) breast cancer is a more aggressive form of breast cancer, affecting about 14% of patients. Thankfully, breakthroughs in targeted
The 2024 ESMO Congress has highlighted significant advances in breast cancer research, aligning with Breast Cancer Canada’s mission to improve patient outcomes. Here are key findings from the congress that
The ESMO Congress 2024 is currently underway in Barcelona, serving as a global hub for the latest advancements in oncology. Researchers, healthcare professionals, and press representatives from around the world
Last week, Breast Cancer Canada had the privilege of participating in the Canada’s Drug Agency (CDA) Symposium 2024, held both in-person at the Ottawa Shaw Centre and virtually. The event,


















Quick Links
Sign Up, Know More.